- Q2 2024 Medivir AB Earnings Call Transcript5 days agokr2.93Earnings
- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr3.57Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr7.35 (+5.00%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr7Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr7.92Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.92Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr7.92Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr8.05Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr8.05Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr8.35Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr9.99Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr10.56 (-5.55%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr7.88Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr8.66Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr14.06Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr16.6Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr11.44Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr14.56Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr21.55Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr24.68Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr19.08Earnings
Q4 2020 Medivir AB Earnings Call Transcript
()-&
Thank you, operator, and warm welcome to our Q4 and full year 2020 webcast. On Slide 3, you will find our -- you will find our presentation on our home page. And on Slide 3, I do recommend everyone to read the disclaimer, which will be, as I said, on our home page as well, for those of you who are interested in the details.
Slide 5, please. This is today's outline where we will briefly touch upon our main projects and then to be rounded off with our Q4 and full year numbers.
Slide 6, please. Medivir has been around as a company since 1988 and started off as a virology-focused company back in the day. The company is listed on NASDAQ here in Stockholm. And our proprietary asset currently is MIV-818, which is a liver-directed nucleotide prodrug. We are currently in Phase Ib clinical development and aim to initiate a combination trial later this year. 818 has received Orphan Drug Designation both in EU and the U.S.
We have made a couple of achievements in the last months. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)